

REMARKS

Applicants respectfully submit that all amendments made to the substitute specification are supported either expressly or inherently in the present application as originally filed, such that no new matter is believed to have been added. The amendment to the specification is intended to solely clarify the terms "epitope gene shuffling" in paragraph 1 of the subject application.

The title has been amended to more particularly describe the subject matter of the application. No new matter has been added.

The amendments to the claims as set forth above are intended to more particularly point out and distinctly claim the subject invention. No new matter has been added.

Deleted language is stricken through and added language is underlined.

The Commissioner is hereby authorized to charge any deficiencies or credit any overpayments in connection with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Date: 10 May 2006

By:


Arles A. Taylor, Jr.
Reg. No.: 39,395

Suite 1200 University Tower
3100 Tower Boulevard
Durham, North Carolina 27707
Telephone: (919) 493-8000
Facsimile: (919) 419-0383

25297
PATENT TRADEMARK OFFICE

1547/5 AAT/shb

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

A METHOD FOR PREPARING EPITOPE CHIMERIC GENE VACCINE A METHOD FOR PREPARING POLYPEPTIDE CHIMERIC GENE VACCINE

Technical field

5

The present invention relates to a new method for artificially producing gene vaccines, designated as Epitopes Assemble Library Immunization (EALI). The method of the invention generally involves the construction of expression libraries of polyepitope chimeric genes with different sizes and 10 lengths using epitope gene shuffling and random assembly so as to screen polyepitope chimeric gene vaccines.

Background art

15 Since the DNA shuffling technique developed by Stemmer was published in Science in 1994, many molecular breeding technologies relating to the artificial evolution of genes have been developed (Juha P. Int Arch Allergy Immunology, 121, 173-182 (2000)), including various improved protocols of gene shuffling (Huimin Z. et al. Nucleic Acids Research, 25 (6), 1307-1308 20 (1997); Andreas C. et al. Nature, 391 (15), 288-291 (1998); Miho K. et al. Gene, 236, 159-167 (1997)), staggered extension process (Huimin Z. et al. Nature Biotechnology, 16, 258-261 (1998)), incremental truncation for the creation of hybrid enzymes (Marc O. et al. Nature Biotechnology, 17, 1205-1209 (1999)) and random chimeragenesis on transient templates 25 (Wayne M.C. et al. Nature Biotechnology, 19, 354-359 (2001)) etc. To date there are many successful examples in which the basic principles of the molecular evolution techniques have been applied to generate or modify genes in fields ranging from the common biological proteases to improvement of antibiotic titre, the degradation of pollutants in the environment, the reconstruction of viruses, and the development of pharmaceuticals. But it is rarely employed in field of DNA vaccines which is 30

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

the third generation of human vaccines. Although many experts predict that the success of gene shuffling technology in gene vaccines will make it widely applicable to diseases such as cancer, autoimmune diseases and infectious diseases which severely harm human health (Dewey D.Y.R et al. 5 Biotechnology Progress, 16 (1), 2-16 (2000); Phillip A P. et al. Current Opinion in Biotechnology, 8, 724-733 (1997); Robert G.W. et al. Curr Opin Mol Ther, 3 (1), 31-36 (2001)), there is no related literature or patents demonstrating substantial progress.

10 Gene vaccines represent a new immunological theory and technique developed in the 1990s and are the third generation of vaccines after attenuated virus vaccines and subunit vaccines (Wolff J. A. et al. Science, 247, 1465-8 (1990)). The technology of gene vaccines comprises the step of direct injection of plasmid DNA containing exogenous protein coding sequences into the body so as to enable the direct expression of the exogenous proteins in the body thereby eliciting an immune response. Gene vaccines have many advantages compared to conventional vaccines, such as prolonged immune response, simultaneous induction of humoral immunity and cytotoxic T cell response, simple preparation, convenience, inexpensive, 15 stable antigen and convenient delivery, and so on. It not only has the safety proved by recombinant subunit vaccines and the high efficiency of attenuated virus vaccines for the induction of a general immune response but also elicits specific types of immune response in the body. Up to now, gene vaccines have been widely used for therapy of infectious diseases and 20 cancer caused by viruses, bacteria and protozoa as well as in the therapy of allergic response and tolerance in new born infants. There is beneficial development in the therapy against influenza, AIDS, rabies, hepatitis B, tuberculosis, malaria and leishmaniasis (Lai W.C. et al. Crit Rev Immunol, 18 (5), 449-84 (1998)). With respect to plasmodium, HIV and other highly 25 variable viruses severely affecting human health, there are no very effective 30 vaccines.

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

For pathogens with highly variable properties, vaccine studies indicate that it is necessary to employ various antigens at various periods (Doolan D.L. et al. Int J Parasitol, 31 (8), 753-62 (2001)). For multiple antigen vaccines, many reports and patents have been published, which focus on single synthetic or recombinant vaccines of multiple antigens and polyepitope protein vaccines or the combination of limited types of such synthetic or recombinant vaccines. Moreover, it is problem that the synthesis of polypeptide vaccines is very costly, which hampers its practical application. Now some references report polyepitope chimeric gene vaccines, but the attention concentrates on the artificial and single chimeric pattern among polyepitope genes, and no immunoprotective effect better than that of polypeptide vaccine has been achieved. In view that three antigenic epitopes of *Plasmodium falciparum* (MSA-1, NKND and CST3) were selected during construction of a multivalent recombinant DNA vaccine, the inventors of the present invention carried out different construction and combination of polyepitope genes according to the combination pattern designed in advance and found that there was an optimal assembly in polyepitope combination (Lin C. T. Chinese J of Biochemistry and Molecular Biology, 1999, 15 (6): 974-977). The result indicated that with respect to the combination of a few epitopes (less than 3), the optimal combination may be obtained by manually individual assembly and construction. But as the combination of more epitopes (more than 3) provides many possibilities, it is impractical to assemble and construct by the above method because it is complicated, costly and requires much work. Thus, how to effectively design polyepitope genes and overcome the variability of pathogens is required for the development of gene vaccines (Yu Z. et al. Vaccine, 16 (7), 1660-7 (1998); Kumar S. et al. Trends Parasitol, 18 (3), 129-35 (2002); Hoffman S.L. et al. Dev Biol, 104, 121-32 (2000); Li M. et al. Chin Med J (Engl), 112 (8), 691-7 (1999); Jiang Y. et al. Chin Med J (Engl), 112 (8), 686-90 (1999)).

30

The life cycle of *Plasmodium falciparum* which causes malignant malaria

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

- severely affecting human health is complicated and comprises four stages comprising asexual reproduction and sexual reproduction in humans and sexual reproduction and sporogony in mosquitos. In humans there are exoerythrocytic (liver) and erythrocytic stages, while gametocyte and sporozoite stages are in mosquitos. Such complex biological traits cause *Plasmodium falciparum* to have highly variable response against the immunoprotectiion of the host and drugs, so that single protective antigenic vaccines against malaria are not effective.
- 5
- 10 The clinical symptoms caused by plasmodium are mainly due to its asexual reproduction in the red blood cells of the host. Erythrocytic stage vaccines are designed to act directly against this unique pathogenic stage of plasmodium. Malaria vaccines comprise attenuated circumsporozoite vaccine, subunit vaccine and synthetic peptide vaccine, but they are not
- 15 successful because the various antigens against which various vaccines are directed can not generate satisfactory protective effects. Therefore, it is well accepted in the art that the combination of multi-stage and multivalent epitopes is necessary in the constuction of a malaria vaccine, to make it possible to obtain the desired protective effect. However, it is difficult to
- 20 determine the quantity and linking order of the genes encoding polypeptides during the construction of multi-stage and multivalent vaccines manually, and the induction of humoral immunity by epitope DNA vaccines is generally not satisfactory, which are problems to be solved.
- 25 Summary of the invention

In one aspect of the present invention, a method for preparing polyepitope chimeric gene vaccines is provided, in which gene recombination in random libraries is used to construct new gene vaccines, comprising the steps of:

30

- a) selecting, synthesizing and cloning into a vector a plurality of nucleic

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

- acid molecules each encoding a single epitope of an antigen of interest;
- 5 b) constructing nucleic acid molecules encoding randomly combined bi-epitopes in the vectors of step a) by isocaudamer linkage;
- 10 c) randomly assembling polyepitope chimeric genes with different lengths from the nucleic acid molecules encoding bi-epitopes of step b);
- 15 d) isolating, purifying and amplifying polyepitope chimeric genes according to different length ranges, then subcloning them into expression vectors and transforming prokaryotic hosts, respectively to obtain polyepitope chimeric gene expression libraries in the corresponding length ranges;
- 20 e) detecting differences of polyepitope chimeric genes in each expression library to ensure the high diversity of the gene libraries;
- 15 f) immunizing animals with each polyepitope chimeric gene library, then detecting the immunogenicity of expression products of genes in the polyepitope chimeric gene libraries;
- 25 g) determining one or more gene libraries containing optimally assembled polyepitope chimeric gene vaccines according to the results of step e) and f);
- 20 h) screening polyepitope chimeric gene vaccines with high immunogenicity from gene libraries obtained in step g) by high-throughput immunochemistry methods.
- 25 According to the method of the present invention, the random assembling of polyepitope chimeric genes with different lengths in step c) is carried out simultaneously by following two methods to increase the randomization of tandem recombinations of different epitopes: 1) combined polymerase chain

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

reaction and primer-free polymerase chain reaction; and 2) random linkage using isocaudamer sites in the vector.

According to one aspect of the present invention, the invention provides a
5 polyepitope chimeric gene vaccine prepared by the method of the invention.
In one embodiment of the invention, said polyepitope chimeric gene vaccine
is a polyepitope chimeric gene vaccine directed against *Plasmodium*
falciparum.

10 Description of Figures

Fig. 1 is a scheme showing the random assembling of polyepitope genes. In
the figure, 1: obtaining some single epitope genes, 2: constructing
bi-epitopes by random assembling, 3: primer-free polymerase chain reaction;
15 4: isolation and purification of DNA fragments of different sizes and
establishment of chimeric gene libraries.

Fig. 2 shows a graph of polyepitope genes randomly constructed by using a
primer-free polymerase chain reaction under different conditions, obtained
20 as follow: using the mixture of random assembled bi-epitope genes as
templates (in the concentration of 0.5 μ g/ μ l, 0.5 μ l, 1.0 μ l, and 2.0 μ l,
respectively), and in a 50 μ l system primer-free polymerase chain reaction
was carried out for cycles of 25, 35, 45, 55, 65, 75, and 85, respectively. The
result indicated when the amount of the templates was less than 0.5 μ l
25 (250ng), as the number of cycles increased, the size of the main products of
the amplification was increasing. When the cycles of 65-75 were used, the
length may be about 2kb, and when more than 85 cycles, the fragment was
larger than 4kb.

30 Fig. 3 shows the gene structure of a polyepitope chimeric gene vaccine in an
eukaryotic expression vector. For gene expression analysis, a common

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

epitope sequence (e.g. E6_(MSA-1)) may be inserted downstream of each polyepitope gene.

- Fig. 4 shows the length comparison of genes in different polyepitope chimeric gene libraries, in which M, λ/*Hind*III; 1, genes in No.1 library/*Eco*RI+*Bgl*II; 2, genes in No.2 library/ *Eco*RI+*Bgl*II; 3, genes in No.3 library/*Eco*RI+*Bgl*II; 4, genes in No.4 library/*Eco*RI+*Bgl*II; 5, genes in No.5 library/*Eco*RI+*Bgl*II.
- 10 Fig. 5 shows the diversity analysis of genes in polyepitope chimeric gene libraries with different lengths.
A. shows that the structural diversity of genes in the No.3 gene library is 96% (24/25); B. indicating the structural diversity of genes in the No.4 gene library is 100% (25/25). 25 recombinant clones selected randomly from both
15 libraries were used to perform PCR with primers downstream and upstream of the multiple cloning sites of vector VR1012. The products of amplification were denatured at 100°C for 10min, placed on ice for 10min, and then mixed with 10Xsample buffer for polyacrylamide gel electrophoresis (10%) to analyze the difference between the bands.
- 20 Fig. 6 shows the level of antibodies in mice immunized with the mixed polyepitope chimeric gene vaccines of libraries with different lengths.
Eight epitopes (E2_(NKND), E3_(MSA-2), E5_(EBA-175), E6_(MSA-1), E7_(LSA-1), E8_(CS.T3/CSP), E9_(MSP-1) and E11_(AMA-1)) were mixed to coat microplates with 200ng/well.
25 Five mixed gene libraries were used to immunize Balb/c mice at 100μg DNA with Dendrimer PAMAN G9 (1:6.5, w/w) in order to generate antisera. The antisera were then 2X diluted to measure the value at OD₄₅₀. The positive has a value at least two folds of that of the control.
- 30 Fig. 7 shows the IFA detection of the dilutions of the corresponding antibodies generated by mixed polyepitope chimeric gene vaccines in the

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

libraries with different lengths.

Five gene libraries were used to immunize Balb/c mice twice at 100 μ g DNA to generate antisera, which were 2X diluted. The negative control was used as a reference, and the positive has a fluorescence intensity significantly
5 different from that of the control.

Fig. 8 shows the confocal microscopy results that the antibodies against mixed epitope gene vaccines in No.4 library recognize different native antigens of plasmodium.

10 A. A blood smear of *Plasmodium falciparum* 3D7; B. A blood smear of *Plasmodium falciparum* FCC1; C. A blood smear of *Plasmodium yoelii*.

15 Fig. 9 shows a Western blot result demonstrating that the corresponding antisera against the mixed polyepitope chimeric gene vaccines in No. 3 library recognize native antigens of plasmodium strain 3D7.

1. The culture of strain 3D7 not treated with Spanin; 2. The culture of strain 3D7 treated with Spanin; 3. Red blood cell culture control; M. Low molecular weight standard (97, 66, 45, 30, 20.5, 14.4kDa). The result indicated that after the antisera against the mixed polyepitope chimeric gene vaccine in the
20 No.3 library were 3000X diluted, they still were able to recognize the various 3D7 antigens treated with Spanin.

Fig. 10 shows cross protection by the mixed polyepitope chimeric gene vaccines from different libraries against *Plasmodium yoelii*.

25 In the presence of an empty vector and saline as parallel controls, the mixed polyepitope chimeric gene vaccines from different libraries (Libraries No.2, No.3, No.4 and No.5) were used to immunize Balb/c mice (seven in each group) for three times prior to the challenge with 2X10⁵ infectious *Plasmodium yoelii* by peritoneal injection. The death of mice was observed
30 in every three days. The results indicated that No.2, No.3 and No.4 libraries elicited protective effect, wherein the protection rate of the polyepitope genes

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

from No.3 library (with a size of about 1200bp) was up to 42.8%.

Fig. 11 shows a Western blot of the prokaryotic expression of antigen genes with high immunogenicity. Fig. 11A. SDS-PAGE; Fig. 11B. hybridization membrane. 5 1. positive clone SP312 selected; 2. the vector; 3. negative clone SN33; 4. SN34; 5. SP352; 6. SN36.

Fig. 12 shows the detection of cytokines involved in in vivo immune response elicited by the positive (SP) and negative (SN) clones screened 10 from the libraries.

Detailed description of the invention

The principle of the present invention is illustrated in Fig. 1.

15

According to the method of the invention, the antigen of interest is any antigen related to various infectious diseases, tumors or autoimmune diseases. Many sequences of the antigen epitopes are known in the art, and based on these sequences it is possible to synthesize a plurality of the 20 nucleic acid molecule each nucleic acid encoding a single epitope of an antigen of interest in step a).

After the nucleic acid molecules encoding a single epitope of an antigen of interest are cloned into vectors, these genes encoding a single epitope are 25 randomly assembled to form bi-epitope genes according to the method of the present invention using the isocaudamer technique. Various isocaudamers are known in the art, which may be used in the method of the present invention.

30 According to the method of the invention, after bi-epitope genes are obtained,

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

they need to be randomly assembled into polyepitope chimeric genes. To increase the randomicity of the tandem recombination between different epitopes, in one preferable embodiment of the present invention, two approaches are carried out simultaneously to randomly assemble 5 polyepitope chimeric genes with different lengths: 1) combined polymerase chain reaction and primer-free polymerase chain reaction; and 2) random linking with the aid of the isocaudamer sites on the vector.

The obtained randomly assembled polyepitope chimeric genes with different 10 lengths are separated according to the various length ranges which may be set according to the requirments and which are usually from hundreds to thousands of base pairs. In one embodiment of the invention, five groups of randomly assembled polyepitope chimeric genes of respectively 300, 800, 1200, 2000 and 4000bp are separated. It is understood that one skilled in 15 the art may set any desired length ranges. Then these separated groups of polyepitope chimeric genes may be cloned into any appropriate expression vector known in the art after being purified and amplified, and used to transform appropriate host cells to obtain several expression libraries of polyepitope chimeric genes.

According to the invention, after expression libraries of polyepitope chimeric 20 genes are obtained, the diversity of the libraries and the immunogenicity of the expression products of the libraries are detected, so that one or more gene libraries comprising optimally assembled polyepitope chimeric gene 25 vaccines are selected to further screen and prepare polyepitope chimeric gene vaccines. Preferably, the diversity of the libraries is above 85%. The criteria to determine the optimal assembly are based on the high diversity of the libraries and high immunogenicity of the expression products. In addition, the criteria may include the immunological characteristics related to the 30 antigen epitopes of interest, such as the specific immunological types and cytokines generated in the body elicited by the libraries tested or the cross

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

protective effects elicited in animal models.

In the examples of the invention, the inventors selected antigen epitope sequences which were proved to be high immunogenic in the literature on 5 *Plasmodium falciparum* (Table 1), and using human preferential codons modified the corresponding coding sequences (Table 2). Fourteen epitope fragments were repeated and then ligated randomly to construct artificial antigen libraries with different lengths wherein each library contained thousands of artificial antigens of different combination. After mice were 10 immunized with the polyepitope gene libraries, a very high level of specific antibody was obtained in the serum. With a *Plasmodium yoelii* mouse model, it had been demonstrated that these artificial antigens were able to elicit cross-immunol protection, thereby indicating that the expression libraries constructed according to the method of the present invention overcame the 15 drawbacks in the existing libraries and laid a foundation for ideal polyepitope chimeric gene vaccines. The primary screening result for the libraries in Example 6 indicated that polyepitope chimeric gene vaccines with higher immunogenicity may be obtained by high-throughput immunochemistry methods.

20

The advantages of immunization of the body with the chimeric gene expression libraries according to the invention, which differ from that with cDNA expression libraries, lie in that the polyepitope chimeric gene libraries eliminate the interference of non-epitope DNA sequences associated with 25 the use of cDNA expression libraries (Shibui A. et al. Res Commun Mol Pathol Pharmacol, 109 (3-4), 147-57 (2001); Smooker P. M. et al. Vaccine, 18 (23), 2533-40 (2000); Johnston S.A. et al. Vaccine, 15 (8), 808-9 (1997)), and improve the safety of gene vaccines. Also one skilled in the art could select targets for gene immunization and challenge, prepare more quickly 30 efficient gene vaccines, and recognize the genes in libraries which indeed have protective effect so as to facilitate analysis of gene function.

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

In the following examples, polyepitope chimeric gene vaccines against malignant malaria were prepared. These examples are intended to illustrate the invention only, not limit the scope of the invention. One skilled in the art would understand that the method of the present invention is not limited to the preparation of polyepitope chimeric gene vaccines against malignant malaria, but may be used in the preparation of gene vaccines against various infectious diseases, tumors or autoimmune diseases.

- 10 The invention is further illustrated in detail by the following figures and examples.

Example 1: Cloning and sequence analysis of the functional fragments of the epitope gene fragments of *Plasmodium falciparum*

- 15 1. Modification of the DNA sequences encoding epitopes of B cells and Th cells in different life stages

In order to inhibit the growth of *Plasmodium falciparum* more effectively and 20 test the protection in a *Plasmodium yoelii* animal model of malaria, fourteen epitopes from nine surface antigens MSP-1, RESA, MSA-2, AMA-1, EBA-175, LSA-1, CS.T3, NKND and MAg-1 found in various life stages of *Plasmodium falciparum* which are homologous to those of *Plasmodium yoelii* were selected (Table 1) based on the published literatures, wherein the 25 nucleotide sequences corresponding to the amino acid sequences of the epitopes were generated using human preferential codons (Table 2, the nucleotide sequences in bold).

- 30 2. Design and synthesis of primers for the epitope gene fragments
a) Based on the epitope gene sequences modified in above step 1, two

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

primers with complete complementary 3' ends were designed (Table 2, the complementary sequences were the overlapping sequences between two primers), and isocaudamer sites of *BclI* and *BamHI* were introduced into the upstream and downstream primers for the epitope gene sequences,
5 respectively.

b) A structure of GLy-Pro-Gly-Pro (G-P-G-P) was introduced near the *BclI* and *BamHI* linkage site of the different linked antigen epitopes in order to

increase the steric flexibility of the epitope linkages.

10

c) For longer epitope gene fragments (such as E3_(MSA2) and E6_(MSA1)), four primers were used to obtain the full-length genes by twice annealing and extension.

15 3. Cloning and sequence analysis of the epitope gene fragments

a) The matched sequences between the two complementary primers were allowed to anneal and extend under the PCR conditions of 94°C, 30sec, 45-60°C (depending on the Tm of different primers), 30sec, and 72°C, 40sec,
20 40 cycles.

b) The amplification products were precipitated by 1/10 volume of 10M ammonium acetate and 2 volume of pure ethanol, then resolved in ultra-purified water, digested with *BclI* and *BamHI* and treated with equal
25 volume of phenol, followed by centrifugation at 12000rpm for 5 min. The supertanant was precipitated by 1/10 volume of 3M sodium acetate and 2 volume of pure ethanol, and then resolved in ultra purified water.

c) The digested product was ligated to vector VR1012 (Vical Inc.) which had
30 been digested with same enzymes, and then transformed into *E. coli* strain SK383 (deficient in GATC methylation). The target clones were selected by

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

*BcI*I and *Bam*H I cleavage.

- 5 d) The target clones were sequenced with primer C038P which has a sequence of 5'-CCAGACATAATAGCTGAC-3' and which is a sequence upstream the multiple cloning sites of vector VR1012.

Example 2: Random assembly of epitope genes of *Plasmodium falciparum*

1. Construction of randomly assembled bi-epitope genes

10

To generate matched regions among epitope genes which have very low homology, the individual single epitope genes cloned in step 3 of Example 1 were ligated to form bi-epitope genes by using isocaudamer sites of *BcI*I and *Bam*H I in conjunction with a *Hind*III site. Briefly, for the randomization of 15 ligation and improvement of efficiency, various single genes were mixed in equal amounts and divided into two aliquots. One was cleaved with *BcI*I and *Hind*III, the other with *Bam*H I and *Hind*III. And the fragments from the two digestions which contain epitope genes were mixed and ligated, then electrotransformed into *E. coli* strain SK383 to obtain clones containing 20 randomly assembled bi-epitope genes.

2. Construction of randomly assembled polyepitope genes of different lengths

25 In order to increase the randomness of the recombination of different epitopes, two protocols, polymerase chain reaction and random linkage by isocaudamers, were used to construct the randomly assembled polyepitope genes, and finally the products from these two protocols were mixed to construct five polyepitope gene libraries (Fig. 4) with different lengths (about 30 300, 800, 1200, 2000 and 4000bp, respectively).

SUBSTITUTE SPECIFICATION -MARKED UP VERSION

Attorney Docket No. 1547/5

a) Construction by polymerase chain reaction

The bi-epitope recombinant plasmids in above step 1 were mixed, subsequently cleaved with *Bcl*I and *Bam*HI, and subjected to electrophoresis 5 on a low melting point agarose gel. The small fragments were retrieved with DNA purification kits (Promega), and measured at OD₂₆₀/OD₂₈₀ for their concentrations.

A reaction system for primer-free polymerase chain reaction (50μl) was 10 prepared with the following components:

Mixed bi-epitope DNAs	1μl
ExTaq DNA polymerase (5U/μl)	2U
10X buffer	5μl
dNTP	8μl
15 d ₂ H ₂ O	36μl

The reaction conditions (25, 35, 45, 55, 65, 75, or 85 cycles) were as follows. First procedure, 94°C, 3min; 94°C, 30sec; 42-55°C, 30sec; 72°C, 30sec; 25 cycles; and 72°C, 10min. Second procedure: 94°C, 3min; 94°C, 45sec; 20 50-55°C, 45sec; 72°C, 30sec, 1sec/cycle; 10 cycles; and 72°C, 10min. The products of the primer-free amplification were subjected to 1% agarose gel electrophoresis and the results were shown in Fig 2, which showed that the assembled polyepitope gene fragments had increased length with the increase of the cycle number. Five DNA fragments with different lengths 25 (about 300, 800, 1200, 2000 and 4000bp, respectively) were retrieved from the gel and subjected to a conventional PCR reaction with upstream primer 5'-ACATCATGCCTGATCA-3' and downstream primer 5'-TTAGCTAGCGGATCC-3'. The reaction system was the same as that for the primer-free PCR, with a procedure: 94°C, 3min; 94°C, 30sec; 50°C, 30sec; 72°C, 30sec; 30 cycles; and 72°C 10min. The amplification products were purified and concentrated by wizard PCR prep purification kit

SUBSTITUTE SPECIFICATION -MARKED UP VERSION

Attorney Docket No. 1547/5

(Promega), then cleaved with *Bcl*I and ligated into vector VR1012 which had been cleaved with EcoRV and *Bcl*I, and the ligation mixture were electrotransformed into E. coli strain SK383. The methods and results were set forth in Fig. 1 and Fig. 2.

5

b) Random linkage by isocaudamers

The bi-epitope recombinant plasmids in above step 1 were mixed. Small fragments cleaved with *Bcl*I/*Bam*HI (containing epitope genes) were ligated 10 with large fragments cleaved with *Bam*HI/*Hind*III (containing epitope genes), and then the ligation mixture was electrotransformed into competent cells SK383 to form random assembled tetra-epitope libraries. Similarly, five random libraries of polyepitope genes with different lengths (about 300, 800, 1200, 2000 and 4000bp, respectively) were constructed.

15

Example 3: Construction of expression libraries of polyepitope chimeric genes of *Plasmodium falciparum*

20 1. Construction of eukaryotic expression vectors VR10A and VR10T containing Kozak sequence and termination codon, respectively.

Primers(1A: 5'-GATCACCATGGAATTCTG-3' and 1B:
5'-GATCCGAATTCCATG

25 GT-3') containing eukaryotic Kozak sequence were designed and then were allowed to self anneal and extend. The PCR product was cleaved with *Bcl*I and *Bam*HI and cloned into vector VR1012 with E. coli strain SK383 as the recipient strain, thereby a recombinant plasmid VR10A was obtained and sequenced by Takara Biotech Company.

30

In order to facilitate the subsequent functional analysis of polyepitope genes

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

after the random construction, the termination codon TAATAA was placed downstream of the epitope E6_(MSA-1) (Table 2, primer 6D for gene E6). Primers 6A, 6B, 6C and 6D were synthesized, and allowed to self anneal and extend. The PCR product was cleaved with *Bc*_{II} and *Bg*_{II} and cloned 5 into vector VR1012 with *E coli* strain SK383 as the recipient strain, thereby a recombinant plasmid VR10T was obtained and sequenced by Takara Biotech Company.

10 2. Construction of five expression libraries of polyepitope genes with different lengths

15 a) Plasmid DNAs from the five polyepitope gene libraries with different lengths prepared in step 2 of Example 2 were cleaved with *Bc*_{II} and *Hind*_{III}. The obtained fragments (containing epitope genes) were retrieved and respectively ligated with plasmid VR10A cleaved with *Bam*_{HI} and *Hind*_{III} 20 (containing start codon), then electrotransformed into competent cells SK383 to obtain recombinant plasmids.

25 b) Similarly, five recombinant plasmids in step a) were cleaved with *Bc*_{II}/*Hind*_{III} and *Bam*_{HI}/*Hind*_{III} and ligated with the DNA fragment of vector VR10T in above step 1 containing the termination codon to construct five expression libraries (No.1, No.2, No.3, No.4 and No.5, respectively) of polyepitope genes with different lengths (about 300, 800, 1200, 2000 and 4000bp, respectively), as shown in Fig. 4.

20 3. Analysis of gene diversity of the expression libraries of polyepitope chimeric genes

30 Libraries No.3 and No.4 were tested for the single-strand conformation polymorphism (PCR-SSCP). The results indicated that the diversity in the chimeric genes of both libraries was higher than 95% (24/25 and 25/25,

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

respectively), as shown in Fig. 5. The steps for this test were as follows:

- a) 25 clones were selected randomly from the libraries and PCR was carried out with primer (C038P: 5'-CCAGACATAATAGCTGAC-3') upstream of multiple cloning sites of vector VR1012 and primer (C039P: 5'-GATGGCTGGCAACTAGAA-3') downstream of multiple cloning sites of vector VR1012 (amplification conditions: 94°C, 30sec; 55°C, 30sec, 72°C, 1min, 30 cycles). The amplification products were incubated in boiling water bath for 10min and chilled on ice for 10min, then mixed with 10X sample buffer.
- b) The above samples were subjected to 10% polyacrylamide gel and ran at 5V/cm. After electrophoresis, the gel was firmly on the glass.
- c) The glass with gel was put into a petri dish and fixing buffer (10% glacial acetic acid v/v) was added to immerge the gel for at least 20 min with horizontally shaking slowly. After fixation, the fixing buffer was collected and used as fixer after development.
- d) The gel was rinsed with double distilled water three times.
- e) A staining solution (2g AgNO₃, 3ml 37% formaldehyde in 2 liters of deionized water) was added and the dish was slowly shaken for 30 min.
- f) The gel was rinsed with double distilled water for 20sec (note: the rinse time should not be too long).
- g) A precooled developing solution (60g Na₂CO₃, 3ml 37% formaldehyde, 400μl 10mg/ml sodium thiosulfate were added in 2 liters of deionized water, and placed in water bath until the temperature was 10-12°C) was added and the dish was slowly shaken until the bands were visualized in gel (usually

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

5-6 min).

h) An equal volume of fixing solution was added into the dish to stop the developing reaction, and the dish was slowly shaken for 2-3 min.

5

i) The gel was rinsed with double distilled water three times.

j) The gel was air-dried and detected under lamp.

10 Example 4: Detection of the immunogenicity of the five polyepitope gene libraries

1. Preparation of recombinant plasmids containing the polyepitope genes of different libraries

15

Bacteria containing the polyepitope gene libraries with different lengths (No.1, No.2, No.3, No.4 and No.5) constructed in step 2 of Example 3 were washed respectively from the plates, and cultured in LB liquid medium with corresponding antibiotics. Then a inoculum was used to inoculate 1 liter of

20 LB liquid medium with corresponding antibiotics at a ratio of 1:100, and the bacteria were cultured to logarithmic growth phase. The bateria were collected. Plasmids were extracted according to Wizard Megapreps plasmid extraction kit (Promega). DNA concentration was calculated from OD₂₆₀/OD₂₈₀ measured with DU70 ultraviolet spectrophotometre (Beckman).

25

2. Preparation of antisera of mice immunized with the polyepitope chimeric gene libraries

30 100µg DNAs of the recombinant plasmids of the gene vaccine libraries obtained in above step 1 were adjusted to equal vluome with sterile saline. Groups of Balb/c mice were immunized by injecting equal volume of such

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

DNAs into humerus quadriceps of both legs, with three animals in each group. The empty vector and blank without DNA were taken as controls. Immunization was boosted every two weeks, totally three times. Blood samples were taken from each group and the polyclonal antisera were collected after immunization.

3. Detection of antibody levels generated by different polyepitope gene libraries by enzyme linked immunosorbent assay (ELISA)

10 In the presence of positive control, negative control and blank control, mixed epitope synthetic peptides were used as coating antigens. The antisera to be tested were two-fold diluted (such as 400, 800, 1600, 3200, 6400, 12800, 25600 and 51200). The maximal dilution (titre) of the antisera after immunization with different polyepitope gene libraries were detected by ELISA, 15 as shown in Fig. 6. The results indicated that the gene libraries with different lengths had different immunogenicity and high titers of antibodies were generated. The specific steps for the assay were as follows:

a) Coating: synthetic peptides of a single or mixed epitopes were used as 20 coating antigens, and diluted with a coating buffer of 0.1M carbonate, pH 9.2 into a desired concentration (200ng/100μl/well). 100μl was added into each well by a pipet and then the plate was placed in humidified environment overnight at 4°C or for 4h at 37°C. The plate was decanted and rinsed with PBST five times.

25 b) Blocking: 200μl of 1% BSA was added into each well, and the plate was incubated at 37°C for 1h.

c) The plate was rinsed with PBST five times.

30 d) Addition of antisera derived from mice to be tested: the antisera to be

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

tested were two-fold diluted with PBS solution, and 100 μ l of the diluted antisera with each concentration in triplicate was added into each well and incubated overnight at 4°C.

- 5 e) The plate was rinsed with PBST five times.
- 10 f) Addition of an antibody labeled with horseradish peroxidase, i.e. horse-anti-mouse IgG-HRP: 100 μ l of the labeled antibody diluted with PBS/BSA (1:1000) was added into each well and incubated for 2h at 37°C in humidified environment.
- 15 g) The plate was rinsed with PBST five times.
- 20 h) Development: 100 μ l of a substrate developing buffer was added into each well and the plate was placed at room temperature for 10min.
- i) 50 μ l of 1M H₂SO₄ was added into each well to stop reaction.
- j) The absorbance at 450nm was read with Labsystems Genesis V3.03 system and the result was analyzed.

Substrate developing buffer (pH5.0)

- Solution A: 1.92g of citrate (anhydrous) was added into ddH₂O with a final volume of 100ml.
- 25 Solution B: 7.16g of Na₂HPO₄ (containing 12 water of crystallization) was added into ddH₂O with a final volume of 100ml.

2.43ml of Solution A, 2.57ml of Solution B and 5ml of water were mixed to form 10ml of phosphate-citrate buffer, pH5.0.

- 30 Prior to developing reaction, 0.015ml of 30% Hydrogen peroxide and 0.004g

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

of TMB were added into the 10ml of phosphate-citrate buffer to freshly prepare the developing buffer.

4. Detection results of indirect immunofluorescence assay (IFA) for the
5 recognition of native proteins by the polyclonal antisera generated by the
different polyepitope gene libraries

In order to determine whether or not the antisera generated by the different polyepitope gene libraries recognize native proteins of *Plasmodium falciparum* and *Plasmodium yoelii*, an indirect immunofluorescence assay (IFA) was used. In the presence of a positive control, the maximum dilution of antibody which permits the recognition was determined and confocal microscopy was used to determine the binding sites of antibody, the results were shown in Figs. 7 and 8. The specific steps of this assay were as follow:

15

- 1) Recognition of native proteins of *Plasmodium falciparum*

a) Blood cells with erythrocytic stage *Plasmodium falciparum* 3D7(or FCC1) (with an infection rate of about 2%) were uniformly spread on slides and the
20 slides were air-dried at room temperature.

b) 100% acetone was used to fix the cells for 10min.
c) The slides were air-dried at room temperature and marked with a
25 fluorescent marker pen, and 1% BSA in PBS was added to block for 30min at room temperature.

d) The slides were rinsed with PBS three times, each for 10 min, and air-dried.

30

- e) Different dilutions (1:500, 1:1000, 1:2000, 1:4000) of the primary antisera

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

(the antisera from the mice as above) were added, and the slides were incubated at room temperature for 30min in humidified environment. MAb M26-32 was taken as a positive control.

5 f) The slides were rinsed with PBS three times, each for 10min, and air-dried.

g) A horse-anti-mouse IgG labeled with FITC diluted by 1:100 was added, and the slides were incubated at 37°C for 30min in humidified environment.

10

h) The slides were rinsed with PBS three times, each for 10min, and air-dried.

15

i) A coverslip was sealed on the slide by 50% glycerol and fluorescent microscopy or confocal fluorescence microscopy were used to visualize.

2) Cross-recognition of native proteins of *Plasmodium yoelii*

20

a) Blood cells with *Plasmodium yoelii* (with an infection rate of about 50%) was uniformly spread on slides and the slides were air-dried at room temperature.

b) other steps were same as those for the recognition of native proteins of *Plasmodium falciparum* in above section 1).

25

5. Western Blot detection of antisera generated by the various polyepitope gene libraries

30

In order to show the recognition of the native antigens of *Plasmodium falciparum* by the antisera generated by the various polyepitope gene libraries, antisera obtained in step 2 of Example 4 were diluted, and

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

subjected to Western blot with the parasite proteins which had been isolated by SDS-PAGE from the Spanin-treated *Plasmodium falciparum*. Polyepitope library No.3 was used in the experiment, and the result indicated that the antisera generated by the gene vaccines in library No.3 recognized more than ten parasite proteins with different sizes, and had high level of antibodies. The result was shown in Fig. 9. The specific steps for this experiment were as follow:

a) Treatment of the sample: the culture of one or two dishes of *Plasmodium falciparum* strain 3D7 was collected by centrifugation, washed with PBS twice, and treated with Spanin at a final concentration of 0.2% to rupture red blood cells. Then the pellet was washed with PBS twice, resolved in PBS, mixed with 10X sample buffer and incubated in a boiling water bath for 10min.

b) Immunoblotting: the treated sample was subjected to SDS-PAGE electrophoresis for separation. After electrophoresis, proteins were electrotransferred onto a nitrocellulose membrane, and then the membrane was blocked by 3% BSA at room temperature for 1h, and rinsed with PBS three times. A given amount of the antiserum generated by the gene library diluted with BSA was added and the membrane was incubated at room temperature for 1h. After the membrane was washed with PBS three times, a secondary antibody horse-anti-mouse IgG (Ap-IgG) labeled with alkaline phosphatase was added and incubated at room temperature for 1h. The membrane was washed with PBS three times. Finally the membrane was rinsed with an alkaline phosphatase buffer (100mmol/L Tris-HCl (pH9.5), 100mmol/L NaCl, 5mmol/L MgCl₂) once.

c) Development and stopping the development: 33μl of nitroblue tetrazolium (50mg/ml in 70% dimethylsulfoxide) and 16.5μl of 5-bromo-4-chloro-3-indo-lyl-phosphate solution (10mg/ml in 100%

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

dimethylsulfoxide) were added per 5ml of alkaline phosphatase buffer. After 10min, a stop buffer (20mmol/L Tris-HCl (pH8), 5mmol/L EDTA) was added to stop the reaction.

5 Example 5: Cross-protection against *P. yoelii* by polyepitope chimeric gene vaccines from different libraries

In order to construct polyepitope chimeric gene vaccines against malignant malaria more efficiently, we tested the protection role of the gene vaccines 10 of the invention in a *P. yoelii* animal model. The result indicated that the five polyepitope gene libraries all exhibited protection with varying extent (Fig. 10), which laid a foundation for an *in vivo* protection model related to the protection role of the artificial shuffled gene vaccines against *Plasmodium falciparum*. The specific steps of the experiment were as follow:

15

a) A sample of *P. yoelii* was removed from liquid nitrogen and thawed at 37°C water bath. 500μl of the sample was injected into Balb/c mice peritoneally. Several days later, a blood sample was taken and spread on a slide, fixed by methanol, and stained with Giemsa and infection rate was 20 counted under a microscope.

b) The blood of mice infected with *P. yoelii* was collected from the tails and dropped into CPBS buffer (NaCl 3.2g, KCl 0.08g, Na₂HPO₄·12H₂O 1.16g, KHPO₄ 0.08g, Na-citrate 3.8g, adding water to 500ml, pH7.2). The 25 concentration of the red blood cells infected by the parasite was calculated by a haemacytometer.

c) Balb/c mice immunized in step 2 of Example 4 were injected peritoneally with the blood obtained as above at a dose of 2X10⁵ red blood cells 30 infected/mouse.

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

- d) Every three days, antisera were collected from the tails of the mice and spread on slides to calculate the infection rate. Also the survival rates of the control and experiment groups were observed.
- 5 Example 6: *In vivo* test of the polyepitope chimeric gene vaccines with high immunogenicity obtained by high-throughput immunochemistry method

According to the results from the *in vivo* immunogenicity test of the polyepitope gene libraries (Example 4) and the test of the protection against
10 *P. yoelii* challenge (Example 5), the polyepitope gene libraries with high level of immunologic response and protection were selected. According to the screening protocol of high-throughput immunochemistry, several positive clones with high immunogenicity were obtained. In the presence of the negative gene clones and empty vectors randomly selected, Western blot
15 detection was carried out for the prokaryotic expression, and cytokines CD4 and CD8 involved in the immunologic response in mice were examined.

1. Western blot detection for the prokaryotic expression
- 20 The result indicated that high immunogenic genes SP312 and SP352 obtained by screening expressed corresponding proteins. After the antibodies generated by use of these two genes were highly diluted, positive hybridization band was still found by Western blot detection, while no signal band was observed when using low immunogenic genes SN33, SN34, and
25 SN36 and empty vector negative control, indicating that polyepitope genes SP312 and SP352 generated higher titre of antibody than genes SN33, SN34 and SN36 (Fig. 11).
- 30 2. Detection of cytokines CD4 and CD8 involved in the immunologic response in mice

SUBSTITUTE SPECIFICATION –MARKED UP VERSION

Attorney Docket No. 1547/5

The obtained positive (high immunogenic) gene clones SP312, SP352 and SP462 were confirmed by *in vivo* immunization. In the presence of negative (low immunogenic) gene clones and empty vector, Balb/c mice were immunized three times, and spleen lymphocytes were isolated for the detection of cytokines CD4 and CD8 using flow cytometry. The results indicated that positive (high immunogenic) gene clones SP312, SP352 and SP462 predominantly induced the production of cytokine CD4, accompanied with certain level of cytokine CD8, wherein positive polyepitope gene SP312 generated a level of cytokines markedly higher than that of SP352 or SP462.

5

10 In contrast, negative polyepitope genes behaved similar to empty vector, demonstrating that polyepitope chimeric gene vaccines with higher immunogenicity can be obtained by high-throughput immunochemistry method (Fig 12).

SUBSTITUTE SPECIFICATION -MARKED UP VERSION

Attorney Docket No. 1547/5

Table 1. Amino acid sequences of B- and Th- cell epitopes of antigens of *Plasmodium falciparum* in different life stages used in the invention

Epitope gene	Amino acids sequence	Antigen gene	Life stage	Types of immunocyte	Reference
E2 _(NKND)	NKNDNKND	NKND	Cross	B	Cheng Q, 1991
E3 _(MSA-2)	KNESKYNSNTFINNAYNMSIRRSM	MSA-2	Erythrocytic stage	B/Th	Symthe JA, 1991
E4 _(RESA)	EENVEHDA	RESA	Erythrocytic stage	B	Chauhan VS, 1993
E5 _(EBA-175)	EREDERTLTKEYEDIVLK	EBA-175	Erythrocytic stage	B	Sim BK, 1994; 1998
E6 _(MSA-1)	LDNIKDNVGKMEDYIKKNKK	MSA-1	Erythrocytic stage /liver stage	B/Th	Kumar A, 1992; Chauhan VS, 1993
E7 _(LSA-1)	EQQSDELQERL(R)AKEKLQ	LSA-1	liver stage	B/Th	Aidoo M, 2000
E8 _(CS.T3/CSP)	KKIAKMEKASSVFNV	CS.T3/CSP	sporozoite stage	Th	Sinigaglia F, 1998
E9 _(MSP-1)	NSGCFCRHLDEREECKCLL	MSP-1	Erythrocytic stage	B	Chang SP, 1992
E10 _(MSP-1)	EDSGSNGKKITCECTKPDS	MSP-1	Erythrocytic stage	B	Chang SP, 1992
E11 _(AMA-1)	DGNCEDIPIVNEFSAIDL	AMA-1	Erythrocytic stage	B	Shi YP, 1999
E12 _(AMA-1)	GNAEKYDKMDEPQHYGKS	AMA-1	Erythrocytic stage	B	Lal AA, 1996
E15 _(AMA-1)	DQPKQYEQQHLTDYEKIKEG	AMA-1	Erythrocytic stage	Th	Lal AA, 1996
E16 _(MSP-1)	GISYYEKVLAKYKDDLE	MSP-1	Erythrocytic stage	Th	Udhayakumar V, 1995
E17 _(MAG-1)	QTDEIKNDNI	MAG-1	Erythrocytic stage	B/Th	Lu Y, unpublished

SUBSTITUTE SPECIFICATION -MARKED UP VERSION

Attorney Docket No. 1547/5

Table 2. Primer sequences for cloning epitope genes

Epitope genes	Primer sequence
E2(_{NKND})	2A: 5' -ACATCATGCC <u>T</u> 'GATCAAACAAGAACGACAACA-3' A <u>C</u> <u>B</u> B <u>D</u>
E3(_{MSA-2})	2B: 3' -TGTTCTTGT <u>G</u> TTC <u>T</u> TGCTGC <u>C</u> CTAG'GGC-5' <u>B</u> <u>C</u> <u>B</u> <u>D</u>
E4(_{RESA})	3A: 5' -ACATCATGCC <u>T</u> 'GATCAAAGAACGAGCAAGTACAG-3' <u>B</u> <u>C</u> <u>B</u> <u>D</u>
E5(_{EBA-175})	3B: 3' -GCTCTGTTCAT <u>G</u> T <u>C</u> GTTGGAA <u>G</u> TAG <u>T</u> TG <u>G</u> GAT <u>G</u> -5' 3C: 5' -CATCAA <u>A</u> ACG <u>C</u> CTACAA <u>A</u> CAT <u>G</u> AG <u>C</u> AT <u>C</u> GG <u>G</u> CA <u>G</u> AT <u>G</u> G-3' 3D: 3' -GGCGGCGTC <u>G</u> T <u>C</u> GA <u>C</u> CCGGGG <u>G</u> GG <u>C</u> CTAG'GGC-5' <u>B</u> <u>C</u> <u>B</u> <u>D</u>
E6(_{MSA-1})	4A: 5' -ACATCATGCC <u>T</u> 'GAT <u>C</u> AG <u>G</u> AG <u>A</u> AC <u>G</u> T <u>G</u> G <u>A</u> GC-3' <u>B</u> <u>C</u> <u>B</u> <u>D</u>
E7(_{LSA-1})	4B: 3' -TCCTCTTG <u>C</u> ACT <u>C</u> T <u>G</u> T <u>G</u> C <u>G</u> G <u>C</u> CTAG'GGC-5' <u>B</u> <u>C</u> <u>B</u> <u>D</u>
	5A: 5' -ACATCATGCC <u>T</u> 'GAT <u>C</u> AG <u>G</u> AG <u>A</u> AC <u>G</u> T <u>G</u> G <u>A</u> GC-3' <u>B</u> <u>C</u> <u>B</u> <u>D</u>
	5B: 3' -GACTGGTCC <u>T</u> CAT <u>G</u> T <u>C</u> T <u>G</u> T <u>G</u> C <u>G</u> G <u>C</u> AC <u>C</u> CTGAC <u>G</u> A <u>C</u> T <u>G</u> G <u>C</u> CTAG'GGC-5' <u>B</u> <u>C</u> <u>B</u> <u>D</u>
	6A: 5' -ACATCATGCC <u>T</u> 'GAT <u>C</u> ACT <u>G</u> G <u>A</u> AC <u>A</u> AT <u>C</u> AG <u>A</u> AC <u>G</u> T <u>G</u> GGC-3' <u>B</u> <u>C</u> <u>B</u> <u>D</u>
	6B: 3' -TCCTGTTGC <u>A</u> CC <u>G</u> T <u>T</u> CTAC <u>C</u> T <u>G</u> T <u>A</u> GT <u>T</u> C <u>T</u> T <u>G</u> T-5' 6C: 5' -TACATCAAGAAC <u>A</u> AG <u>G</u> GG <u>C</u> CC <u>G</u> GG <u>A</u> T <u>C</u> CG <u>C</u> -3' 6D: 3' -CGGG <u>C</u> CTAG'GG <u>G</u> AT <u>C</u> G <u>A</u> TT <u>T</u> T <u>C</u> T <u>G</u> A <u>G</u> GG-5' <u>B</u> <u>C</u> <u>B</u> <u>D</u>
	7A: 5' -ACATCATGCC <u>T</u> 'GAT <u>C</u> AG <u>G</u> AG <u>A</u> AC <u>G</u> T <u>G</u> G <u>A</u> GG <u>C</u> CT <u>T</u> GG-3' <u>B</u> <u>C</u> <u>B</u> <u>D</u>
	7B: 3' -GTCCTCGGG <u>A</u> CC <u>G</u> GT <u>T</u> CC <u>T</u> C <u>T</u> GT <u>A</u> GT <u>T</u> CC <u>G</u> GG <u>C</u> CTAG'GGC-5' <u>B</u> <u>C</u> <u>B</u> <u>D</u>

SUBSTITUTE SPECIFICATION -MARKED UP VERSION

Attorney Docket No. 1547/5

E8 _(cs,T3CSP)	8A: 5' -ACATCATGCCT' <u>GATCAAAAGAAGATGCCAAGATGGAGAAGGCCAGCAGC-3'</u> B
E9 _(MSP-1)	8B: 3' -CTCTTCCGGTCGGCACACAAGTTGCACCCGGCCGGCTAG' <u>GCGC-5'</u> BamHI
E10 _(MSP-1)	9A: 5' -ACATCATGCCT' <u>GATCAAACAGGGCTGCTTCCGCACCTGGACGAGCGC-3'</u> B
E11 _(AMA-1)	9B: 3' -TGGACCTGCTCCTCACGTTACGGACGACCTAG' <u>GCGC-5'</u> BamHI
E12 _(AMA-1)	10A: 5' -ACATCATGCCT' <u>GATCAGAGGACAGGGCAGCAAAGGAAAGATCACCTGC-3'</u> B
E13 _(AMA-1)	10B: 3' -GTTCTCTAGTGGACGGCTCACGTGGTCCAGTGGCTAG' <u>GCGC-5'</u> BamHI
E14 _(AMA-1)	11A: 5' -ACATCATGCCT' <u>GATCAGACGGCAACTGGGAGACATCCGCACCGTGAAC-3'</u> B
E15 _(AMA-1)	11B: 3' -TAGGGGGCACTTGGTCAAGTGGTGGTAGCTGGACCTAG' <u>GCGC-5'</u> BamHI
E16 _(MSP-1)	12A: 5' -ACATCATGCCT' <u>GATCAGGCAACGCCAGAAAGTAGACGACAAGATGGACGAGCCG-3'</u> B
E17 _(MSP-1)	12B: 3' -TTCTACCTGCTGGGTCTGTGATGCCCTTCTCGCTCTAG' <u>GCGC-5'</u> BamHI
E18 _(AMA-1)	15A: 5' -ACATCATGCCT' <u>GATCAGACCCGGGAAGGCACTGGAGGACACCTGACCGAC-3'</u> B
E19 _(AMA-1)	15B: 3' -GTCGGGACTGGCTGATGCTCTAGTTCCCTCCCTAG' <u>GCGC-5'</u> BamHI
E20 _(AMA-1)	16A: 5' -ACATCATGCCT' <u>GATCAGGCACTACGCTACTACGAGAAGGTGCTGGCCAAG-3'</u> B
E21 _(AMA-1)	16B: 3' -TTCCACGACGGGTCATGTCCTGCTGGACCTCTAG' <u>GCGC-5'</u> BamHI
E22 _(AMA-1)	17A: 5' -ACATCATGCCT' <u>GATCACAGACCGAGGATCAAGAACGACCATCCAGACCGAT-3'</u> B
E23 _(AMA-1)	17B: 3' -GTGTAGGGTCTGGCTACTTTAATTTTACTATTATAACCTAG' <u>GCGC-5'</u> BamHI